

NCT01700790 comparison:

Summary:
CHIA has 29 criteria while your personal folder has 29 criteria
Total found criteria: 24/29
Total not Found: 5/29
Total Extra: 2
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Be at least 18 years of age and able to give       │ Be at least 18 years of age and able to give       │
│ informed consent                                   │ informed consent                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Diagnosed with TB by criteria per Brazilian        │ Diagnosed with TB by criteria per Brazilian        │
│ Ministry of Health                                 │ Ministry of Health                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Have a good clinical response to TB                │ Have a good clinical response to TB                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Tolerating tuberculosis therapy containing         │ Tolerating tuberculosis therapy containing         │
│ rifampin for the 2 weeks prior to screening,except │ rifampin for the 2 weeks prior to screening,except │
│ for persons taking protease inhibitors at time of  │ for persons taking protease inhibitors at time of  │
│ diagnosis of TB.,. Subjects taking protease        │ diagnosis of TB.,. Subjects taking protease        │
│ inhibitors will be screened and initiate visit 1   │ inhibitors will be screened and initiate visit 1   │
│ within 3 days of starting TB medication            │ within 3 days of starting TB medication            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ HIV positive with documentation present in source  │ HIV positive with documentation present in source  │
│ document                                           │ document                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Have a CD4 cell count greater than 50 cells/mm3if  │ Have a CD4 cell count greater than 50 cells/mm3if  │
│ not taking ART. Persons with cd4 < 50 may be       │ not taking ART. Persons with cd4 \< 50 may be      │
│ enrolled, if it is felt that in the best interest  │ enrolled, if it is felt that in the best interest  │
│ of the patient, that enrollment in the study will  │ of the patient, that enrollment in the study will  │
│ allow for quicker initiation of antiretroviral     │ allow for quicker initiation of antiretroviral     │
│ therapy than referral to another treatment center  │ therapy than referral to another treatment center  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Non-compliance with DOTPlus. Alternatively DOT can │ Non-compliance with DOTPlus. Alternatively DOT can │
│ be done by telephoning patient on a daily basis 5  │ be done by telephoning patient on a daily basis 5  │
│ times a week and having patient annotate taking    │ times a week and having patient annotate taking    │
│ drug in a log which would be reviewed by clinic    │ drug in a log which would be reviewed by clinic    │
│ staff                                              │ staff                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of being treated for tuberculosis in the   │ History of being treated for tuberculosis in the   │
│ prior 2 years unless there is DST, including PCR   │ prior 2 years unless there is DST, including PCR   │
│ testing, showing sensitivity to rifamycin          │ testing, showing sensitivity to rifamycin          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known hypersensitivity to rifampin or rifabutin    │ Known hypersensitivity to rifampin or rifabutin    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Liver enzymes greater than 2 times ULN             │ Liver enzymes greater than 2 times ULN             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Bilirubin greater than 2 times ULN                 │ Bilirubin greater than 2 times ULN                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum creatinine greater than 3 times ULN          │ Serum creatinine greater than 3 times ULN          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hemoglobin less than 7.0 gms even if receiving     │ Hemoglobin less than 7.0 gms even if receiving     │
│ erythropoietin                                     │ erythropoietin                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Absolute neutrophil count less than 750 cells/mm3  │ Absolute neutrophil count less than 750 cells/mm3  │
│ even if receiving G-CSF                            │ even if receiving G-CSF                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Fasting triglycerides greater than 400 mg/dL       │ Fasting triglycerides greater than 400 mg/dL       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Fasting cholesterol > 1.6 upper limits of normal   │ Fasting cholesterol \> 1.6 upper limits of normal  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ GI intolerance of tuberculosis medications         │ GI intolerance of tuberculosis medications         │
│ requiring discontinuation of tuberculosis          │ requiring discontinuation of tuberculosis          │
│ medications                                        │ medications                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Fasting glucose greater 150 mg/dL                  │ Fasting glucose greater 150 mg/dL                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant women                                     │ Pregnant women                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of one of the prohibited medications           │ Use of one of the prohibited medications           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any condition that the investigators feel could    │ Any condition that the investigators feel could    │
│ compromise the use of the current medication       │ compromise the use of the current medication       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Have a CD4 cell count of 50 cells/mm3or less       │ Have a CD4 cell count of 50 cells/mm3or less       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hepatitis B or C infection                         │ Hepatitis B or C infection                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Alcohol or illicit drug use, which in the          │ Alcohol or illicit drug use, which in the          │
│ investigators opinion may affect participation in  │ investigators opinion may affect participation in  │
│ study                                              │ study                                              │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                                 │
╞═════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Antiretroviral naive                                                                                │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Taking Kaletra containing regimen with suppressed viral load                                        │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Taking an NNRTI or integrase containing regimen without prior history of use of PI for more than 2  │
│ weeks                                                                                               │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Taking an NNRTI or integrase containing regimen with prior exposure to PI greater than 2 weeks. It  │
│ must be clearly stated in the source document that PI was switched to another agent for convenience │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Taking another PI containing regimens with suppressed viral load. It must be clearly stated in      │
│ source document that if another PI was used for greater than 2 weeks the regimen was switched to    │
│ another agent for convenience. Subjects with prior history of PI use may be enrolled, if there is a │
│ genotype showing no resistance to Kaletra Other Inclusion criteria                                  │
╘═════════════════════════════════════════════════════════════════════════════════════════════════════╛



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
├───────────────────────────────────┤
│ Must have maximum age of 65 Years │
╘═══════════════════════════════════╛